Use of Pharmacogenetic and Clinical Factors to Predict

Citation Report

#	ARTICLE	IF	CITATIONS
1	Commercial Liability Underwriting Volumes I and II. Journal of Risk and Insurance, 1992, 59, 350.	1.6	1
2	Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. European Journal of Clinical Pharmacology, 2008, 64, 953-960.	1.9	33
3	Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans. Clinical Pharmacology and Therapeutics, 2008, 84, 332-339.	4.7	108
4	Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice. Clinical Pharmacology and Therapeutics, 2008, 84, 287-294.	4.7	141
5	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. Journal of Thrombosis and Haemostasis, 2008, 6, 1450-1452.	3.8	8
6	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. Journal of Thrombosis and Haemostasis, 2008, 6, 1445-1449.	3.8	14
7	Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. Journal of Thrombosis and Haemostasis, 2008, 6, 1655-1662.	3.8	81
8	Translation towards personalized medicine in Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 274, 68-75.	0.6	28
9	Overview of Pharmacogenetics in Anticoagulation Therapy. Clinics in Laboratory Medicine, 2008, 28, 513-524.	1.4	16
10	Dynamic Pharmacogenetic Models in Anticoagulation Therapy. Clinics in Laboratory Medicine, 2008, 28, 539-552.	1.4	10
11	Duration of Anticoagulation Therapy for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2008, 2008, 252-258.	2.5	25
12	*VKORC1* polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans. Pharmacogenomics, 2008, 9, 1445-1458.	1.3	106
13	*VKORC1* polymorphisms in Amerindian populations of Brazil. Pharmacogenomics, 2008, 9, 1623-1629.	1.3	14
14	Influence of *CYP2C9* and *VKORC1* on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans. Pharmacogenomics, 2008, 9, 511-526.	1.3	142
15	Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose. American Journal of Clinical Pathology, 2008, 129, 876-883.	0.7	74
16	Removing barriers to a clinical pharmacogenetics service. Personalized Medicine, 2008, 5, 471-480.	1.5	22
17	Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform â€" from R&D to the clinic. Pharmacogenomics, 2008, 9, 1391-1396.	1.3	2
18	A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity. Journal of Clinical Pharmacology, 2009, 49, 138-146.	2.0	62

#	ARTICLE	IF	CITATIONS
19	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics, 2009, 10, 1687-1695.	1.3	131
20	Counterpoint: Pharmacogenetic-Based Initial Dosing of Warfarin: Not Ready for Prime Time. Clinical Chemistry, 2009, 55, 712-714.	3.2	10
21	Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics, 2009, 10, 1257-1266.	1.3	28
22	Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics, 2009, 10, 1905-1913.	1.3	70
23	Review: Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future. Therapeutic Advances in Neurological Disorders, 2009, 2, 369-377.	3.5	4
24	Integrative genomics and drug development. Pharmacogenomics, 2009, 10, 203-212.	1.3	18
25	Survey on warfarin pharmacogenetic testing among anticoagulation providers. Pharmacogenomics, 2009, 10, 1853-1860.	1.3	31
26	10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics, 2009, 10, 1955-1965.	1.3	20
27	Pharmacogenetics in Hemostasis: Friend or Foe?. Seminars in Thrombosis and Hemostasis, 2009, 35, 042-049.	2.7	5
28	*CYP2C9*8* is prevalent among African–Americans: implications for pharmacogenetic dosing. Pharmacogenomics, 2009, 10, 1243-1255.	1.3	100
29	*VKORC1* haplotypes in five East-Asian populations and Indians. Pharmacogenomics, 2009, 10, 1609-1616.	1.3	16
30	Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy. Clinical Chemistry, 2009, 55, 1861-1868.	3.2	39
31	Information management to enable personalized medicine: stakeholder roles in building clinical decision support. BMC Medical Informatics and Decision Making, 2009, 9, 44.	3.0	52
32	Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin. Journal of General Internal Medicine, 2009, 24, 656-664.	2.6	105
33	Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European Journal of Clinical Pharmacology, 2009, 65, 789-793.	1.9	12
34	Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period. Clinical Pharmacology and Therapeutics, 2009, 85, 379-386.	4.7	32
35	Variability in Response to Medicines in Older People: Phenotypic and Genotypic Factors. Clinical Pharmacology and Therapeutics, 2009, 85, 431-433.	4.7	91
36	Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram. Journal of Thrombosis and Haemostasis, 2009, 7, 1276-1283.	3.8	23

#	ARTICLE	IF	CITATIONS
37	Proteins and Peptides. , 0, , .		5
38	Risk Assessment and Communication Tools for Genotype Associations with Multifactorial Phenotypes: The Concept of â€œEdge Effectâ€•and Cultivating an Ethical Bridge between Omics Innovations and Society. OMICS A Journal of Integrative Biology, 2009, 13, 43-61.	2.0	58
39	Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clinica Chimica Acta, 2009, 406, 143-147.	1.1	22
40	Genetic and clinical factors relating to warfarin dosing. Trends in Pharmacological Sciences, 2009, 30, 375-386.	8.7	126
41	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology, 2009, 54, 1041-1057.	2.8	92
42	Molecular Diagnostics in Hemostatic Disorders. Clinics in Laboratory Medicine, 2009, 29, 367-390.	1.4	4
44	A comparison of data mining approaches in the categorization of oral anticoagulation patients. , 2009, , .		1
45	Successful Translation of Pharmacogenetics into the Clinic. Molecular Diagnosis and Therapy, 2009, 13, 1-9.	3.8	101
46	Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells, Molecules, and Diseases, 2009, 43, 119-128.	1.4	49
47	Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery. American Journal of Health-System Pharmacy, 2009, 66, 123-133.	1.0	42
48	Validation of Clinical Testing for Warfarin Sensitivity. Journal of Molecular Diagnostics, 2009, 11, 216-225.	2.8	53
49	Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience. Mayo Clinic Proceedings, 2009, 84, 1079-1094.	3.0	115
50	Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenetics and Genomics, 2009, 19, 965-971.	1.5	6
51	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenetics and Genomics, 2009, 19, 800-812.	1.5	57
52	Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and Genomics, 2009, 19, 429-436.	1.5	106
53	Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenetics and Genomics, 2009, 19, 781-789.	1.5	48
54	Clinical pharmacy consultation for pharmacogenetic testing. Personalized Medicine, 2009, 6, 183-192.	1.5	4
55	Personalizing antiretroviral therapy: is it a reality?. Personalized Medicine, 2009, 6, 393-408.	1.5	6

#	ARTICLE	IF	CITATIONS
56	Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 2009, 150, 73.	3.9	259
57	Warfarin Pharmacogenetics: Rationale forCYP2C9/VKORC1Genotyping of Patients Prescribed Warfarin. Critical Values, 2009, 2, 14-17.	0.0	0
58	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 2009, 113, 4977-4979.	1.4	73
59	Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 2009, 113, 3925-3930.	1.4	79
60	Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. Blood, 2009, 113, 4125-4126.	1.4	20
61	Referral of patients with thrombocytopenia from primary care clinicians to hematologists. Blood, 2009, 113, 4126-4127.	1.4	8
62	Percutaneous closure of the left atrial appendage in atrial fibrillation: an alternative if standard treatment fails?. Interventional Cardiology, 2009, 1, 119-131.	0.0	0
63	Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Current Drug Metabolism, 2009, 10, 781-834.	1.2	115
64	Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenetics and Genomics, 2009, 19, 226-234.	1.5	135
65	Anticoagulation in children: personalized strategies. Pediatric Health, 2009, 3, 107-109.	0.3	2
66	VKORC1 Pharmacogenomics Summary. Pharmacogenetics and Genomics, 2010, 20, 642-644.	1.5	100
67	Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study. Therapeutic Drug Monitoring, 2010, 32, 338-345.	2.0	41
68	Predicting warfarin dose. Current Opinion in Pulmonary Medicine, 2010, 16, 426-431.	2.6	14
69	Pharmacogenetics of Oral Anticoagulant Therapy. Current Pharmaceutical Design, 2010, 16, 187-203.	1.9	45
70	Pharmacogenetically Tailored Treatments for Heart Disease. Current Pharmaceutical Design, 2010, 16, 2194-2213.	1.9	6
71	Genetic predisposition to adverse drug reactions in the intensive care unit. Critical Care Medicine, 2010, 38, S106-S116.	0.9	52
72	Will there be a role for genotyping in warfarin therapy?. Current Opinion in Hematology, 2010, 17, 439-443.	2.5	7
73	In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood, 2010, 116, 6101-6105.	1.4	79

#	ARTICLE	IF	CITATIONS
74	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 2010, 115, 3827-3834.	1.4	331
75	VKORC1 â^'1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. European Journal of Clinical Pharmacology, 2010, 66, 591-598.	1.9	22
76	Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 2010, 278, 165-188.	4.2	103
77	Atrial Fibrillation in the Elderly. Current Cardiovascular Risk Reports, 2010, 4, 354-360.	2.0	0
78	Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. Journal of Thrombosis and Thrombolysis, 2010, 30, 220-225.	2.1	36
79	On Warfarin Use in Kidney Disease: A Therapeutic Window of Opportunity?. American Journal of Kidney Diseases, 2010, 56, 805-808.	1.9	2
80	Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials, 2010, 11, 108.	1.6	79
81	Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of Thrombosis and Haemostasis, 2010, 8, 95-100.	3.8	65
82	Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of Thrombosis and Haemostasis, 2010, 8, 1018-26.	3.8	57
83	Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. Journal of Thrombosis and Haemostasis, 2010, 8, 1012-1017.	3.8	22
84	Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients. Clinical Pharmacology and Therapeutics, 2010, 87, 57-64.	4.7	116
85	Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. Clinical Pharmacology and Therapeutics, 2010, 87, 459-464.	4.7	186
86	A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans. Clinical Pharmacology and Therapeutics, 2010, 87, 445-451.	4.7	85
87	Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort. Clinical Pharmacology and Therapeutics, 2010, 87, 417-420.	4.7	47
88	Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clinical Pharmacology and Therapeutics, 2010, 87, 572-578.	4.7	202
89	Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2010, 88, 540-547.	4.7	27
90	A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age. Clinical Pharmacology and Therapeutics, 2010, 87, 727-734.	4.7	90
91	Pharmacogenetics in the Brazilian Population. Frontiers in Pharmacology, 2010, 1, 118.	3.5	38

#	ARTICLE	IF	CITATIONS
92	Integrating genomic-based clinical decision support into electronic health records. Personalized Medicine, 2010, 7, 163-170.	1.5	9
93	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. Personalized Medicine, 2010, 7, 319-325.	1.5	5
94	Comparative Effectiveness And Personalized Medicine: Evolving Together Or Apart?. Health Affairs, 2010, 29, 1783-1787.	5.2	17
95	Combined <i>CYP2C9</i>, <i>VKORC1</i> and <i>CYP4F2</i> frequencies among racial and ethnic groups. Pharmacogenomics, 2010, 11, 781-791.	1.3	146
96	Rapid Multiplexed Genotyping for Hereditary Thrombophilia by SELDI-TOF Mass Spectrometry. Diagnostic Molecular Pathology, 2010, 19, 54-61.	2.1	3
98	Personalized healthcare in clotting disorders. Personalized Medicine, 2010, 7, 65-73.	1.5	0
99	Gamma-glutamyl carboxylase and its influence on warfarin dose. Thrombosis and Haemostasis, 2010, 104, 750-754.	3.4	53
100	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Annals of Medicine, 2010, 42, 562-575.	3.8	10
101	Genetic Polymorphism and Susceptibility to Pesticides. , 2010, , 525-549.		0
102	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. Side Effects of Drugs Annual, 2010, , 617-663.	0.6	0
103	Treatment of Venous Thromboembolism in Older People. Journal of Pharmacy Practice and Research, 2010, 40, 309-314.	0.8	0
104	From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. Pharmacogenomics, 2010, 11, 731-737.	1.3	21
105	Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	1.8	7
106	Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. Journal of Molecular Diagnostics, 2010, 12, 283-291.	2.8	62
107	Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 2010, 11, 1149-1167.	1.3	129
108	Warfarin Genotyping Reduces Hospitalization Rates. Journal of the American College of Cardiology, 2010, 55, 2804-2812.	2.8	327
109	The Long and Winding Road to Warfarin Pharmacogenetic Testing. Journal of the American College of Cardiology, 2010, 55, 2813-2815.	2.8	40
110	Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities. Medical Decision Making, 2010, 30, 328-340.	2.4	99

#	Article	IF	Citations
111	Pharmacogenetics of Warfarin. Annual Review of Medicine, 2010, 61, 63-75.	12.2	92
112	Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria. Clinica Chimica Acta, 2010, 411, 1375-1377.	1.1	12
113	A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thrombosis Research, 2010, 125, e259-e264.	1.7	50
114	Pediatric warfarin practice and pharmacogenetic testing. Thrombosis Research, 2010, 126, e144-e146.	1.7	9
115	Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets. Thrombosis Research, 2010, 126, e235-e237.	1.7	1
116	VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thrombosis Research, 2010, 126, e206-e210.	1.7	14
118	Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenetics and Genomics, 2010, 20, 407-413.	1.5	67
119	Rapid Genotyping of Single Nucleotide Polymorphisms Influencing Warfarin Drug Response by Surface-Enhanced Laser Desorption and Ionization Time-of-Flight (SELDI-TOF) Mass Spectrometry. Journal of Molecular Diagnostics, 2010, 12, 162-168.	2.8	11
120	A model for cost effectiveness analysis of using genetic information of oral anticoagulation patients. , 2010, , .		0
121	<i>VKORC1</i> polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics, 2010, 11, 1257-1267.	1.3	23
122	Patient Factors That Influence Warfarin Dose Response. Journal of Pharmacy Practice, 2010, 23, 194-204.	1.0	37
123	Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11, 493-496.	1.3	61
124	Comparative Effectiveness Research and Personalized Medicine. Pharmacoeconomics, 2010, 28, 905-913.	3.3	40
125	Failure of Pharmacogenetic-based Dosing Algorithms to Identify Older Patients Requiring Low Daily Doses of Warfarin. Journal of the American Medical Directors Association, 2011, 12, 633-638.	2.5	20
126	Personalizing medicine with clinical pharmacogenetics. Genetics in Medicine, 2011, 13, 987-995.	2.4	173
127	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology and Therapeutics, 2011, 90, 625-629.	4.7	571
128	Genotype-Based Dosing Algorithms for Warfarin Therapy. Molecular Diagnosis and Therapy, 2011, 15, 255-264.	3.8	15
129	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood, 2011, 118, 3163-3171.	1.4	81

#	Article	IF	Citations
130	Pharmacogenomics of Warfarin dose requirements in Hispanicsâ˜†. Blood Cells, Molecules, and Diseases, 2011, 46, 147-150.	1.4	36
131	Genetic Warfarin Dosing. Journal of the American College of Cardiology, 2011, 57, 612-618.	2.8	123
132	Effect of Chronic Kidney Disease on Warfarin Management in a Pharmacist-Managed Anticoagulation Clinic. Journal of Managed Care Pharmacy, 2011, 17, 523-530.	2.2	55
133	Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmacogenomics and Personalized Medicine, 2011, 4, 123.	0.7	20
134	Principles of drug biotransformation. , 2013, , 72-89.		1
135	Optimization of Anticoagulation with Warfarin for Stroke Prevention: Pharmacogenetic Considerations. American Journal of Therapeutics, 2011, 18, e55-e66.	0.9	6
136	Pharmacogenomics: Application to the Management of Cardiovascular Disease. Clinical Pharmacology and Therapeutics, 2011, 90, 519-531.	4.7	50
139	Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. British Journal of Clinical Pharmacology, 2011, 72, 442-450.	2.4	51
140	Population diversity and the performance of warfarin dosing algorithms. British Journal of Clinical Pharmacology, 2011, 72, 451-453.	2.4	19
141	Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. Journal of Thrombosis and Haemostasis, 2011, 9, 711-718.	3.8	25
142	The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans. Clinical Pharmacology and Therapeutics, 2011, 89, 408-415.	4.7	100
143	Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants. Pharmacotherapy, 2011, 31, 1192-1207.	2.6	45
144	Accuracy of the Pharmacogenetic Dosing Table in the Warfarin Label in Predicting Initial Therapeutic Warfarin Doses in a Large, Racially Diverse Cohort. Pharmacotherapy, 2011, 31, 863-870.	2.6	5
145	Development and Comparison of a Warfarin-Dosing Algorithm for Korean Patients With Atrial Fibrillation. Clinical Therapeutics, 2011, 33, 1371-1380.	2.5	32
146	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. European Heart Journal, 2011, 32, 1909-1917.	2.2	86
147	Personalized vascular medicine: Individualizing drug therapy. Vascular Medicine, 2011, 16, 391-404.	1.5	16
148	Cardiovascular Pharmacogenomics. Circulation Research, 2011, 109, 807-820.	4.5	71
149	Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation. Pharmaceutical Research, 2011, 28, 1100-1111.	3.5	27

#	ARTICLE	IF	CITATIONS
150	Clinical applications of pharmacogenomics guided warfarin dosing. International Journal of Clinical Pharmacy, 2011, 33, 10-19.	2.1	7
151	The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. European Journal of Clinical Pharmacology, 2011, 67, 581-590.	1.9	11
152	Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. European Journal of Clinical Pharmacology, 2011, 67, 1119-1130.	1.9	38
153	Current Role of Pharmacogenomics in Cardiovascular Medicine. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 302-312.	0.9	1
154	Pharmacogenetic Aspects of Coumarinic Oral Anticoagulant Therapies. Indian Journal of Clinical Biochemistry, 2011, 26, 222-229.	1.9	7
155	Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel. Current Neurology and Neuroscience Reports, 2011, 11, 52-60.	4.2	12
157	Clinical Drugs Undergoing Polymorphic Metabolism by Human Cytochrome P450 2C9 and the Implication in Drug Development. Current Medicinal Chemistry, 2011, 18, 667-713.	2.4	41
158	Influence ofCYP2C9andVKORC1Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People. Journal of Clinical Pharmacology, 2011, 51, 1418-1428.	2.0	33
159	Pathology Consultation on Warfarin Pharmacogenetic Testing. American Journal of Clinical Pathology, 2011, 135, 13-19.	0.7	11
160	Using Pharmacogenetics in Real Time to Guide Warfarin Initiation. Circulation, 2011, 124, 2554-2559.	1.6	50
161	High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics, 2011, 27, 1384-1389.	4.1	68
162	Letter to the Editor: Combined *CYP2C9*, *VKORC1* and *CYP4F2* frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics, 2011, 12, 769-772.	1.3	16
163	Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics, 2011, 12, 125-134.	1.3	46
164	Assessing Evidence of Interaction Between Smoking and Warfarin. Chest, 2011, 139, 1130-1139.	0.8	43
165	Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 387-391.	4.4	74
166	Current challenges in personalizing warfarin therapy. Expert Review of Clinical Pharmacology, 2011, 4, 349-362.	3.1	13
167	Pharmacogenomics and Patient Care: One Size Does Not Fit All. Science Translational Medicine, 2012, 4, 153ps18.	12.4	49
168	Pharmacogenomic Applications in the Developing World: The American Continent. Advances in Microbial Ecology, 2012, , 147-159.	0.1	1

#	Article	IF	Citations
169	Prediction of warfarin dose: why, when and how?. Pharmacogenomics, 2012, 13, 429-440.	1.3	66
170	Personalized medicine policy challenges: measuring clinical utility at point of care. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 289-295.	1.4	16
171	A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). Circulation, 2012, 125, 1997-2005.	1.6	217
172	Evaluation of the effect of genetic variations in <i>GATA-4</i> on the phenprocoumon and acenocoumarol maintenance dose. Pharmacogenomics, 2012, 13, 1917-1923.	1.3	6
173	Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation. Journal of Comparative Effectiveness Research, 2012, 1, 225-239.	1.4	3
174	Research Highlights: Highlights from the latest articles in pharmacogenomics of warfarin dosing. Pharmacogenomics, 2012, 13, 861-864.	1.3	2
175	Warfarin Pharmacogenetics: Does More Accurate Dosing Benefit Patients?. Seminars in Thrombosis and Hemostasis, 2012, 38, 661-666.	2.7	8
176	Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. Seminars in Thrombosis and Hemostasis, 2012, 38, 893-904.	2.7	53
177	Risk factors of vitamin K antagonist overcoagulation. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 53-62.	0.5	21
178	Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics Journal, 2012, 12, 306-311.	2.0	46
179	Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics Journal, 2012, 12, 417-424.	2.0	62
180	Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. Journal of Human Genetics, 2012, 57, 665-669.	2.3	25
181	Effect of <i>NQO1</i> and <i>CYP4F2</i> genotypes on warfarin dose requirements in Hispanicâ€"Americans and Africanâ€"Americans. Pharmacogenomics, 2012, 13, 1925-1935.	1.3	59
182	CYP2C9 and VKORC1 Polymorphisms Are Differently Distributed in the Brazilian Population According to Self-Declared Ethnicity or Genetic Ancestry. Genetic Testing and Molecular Biomarkers, 2012, 16, 957-963.	0.7	25
183	The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiology, 2012, 8, 563-576.	1.2	56
184	Cardiovascular Pharmacogenomics: Current Status and Future Directionsâ€"Report of a National Heart, Lung, and Blood Institute Working Group. Journal of the American Heart Association, 2012, 1, e000554.	3.7	17
185	Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. Indian Journal of Human Genetics, 2012, 18, 326.	0.7	9
186	Warfarin Pharmacogenetics. Circulation, 2012, 125, 1964-1966.	1.6	60

#	ARTICLE	IF	CITATIONS
188	Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. Thrombosis and Haemostasis, 2012, 108, 1132-1140.	3.4	18
189	Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood, 2012, 119, 861-867.	1.4	66
190	Pharmacogenomics in Africa. Advances in Microbial Ecology, 2012, , 161-182.	0.1	2
191	Personalized medicine: is it a pharmacogenetic mirage?. British Journal of Clinical Pharmacology, 2012, 74, 698-721.	2.4	61
193	Clinical Pharmacogenomics of Warfarin and Clopidogrel. Journal of Pharmacy Practice, 2012, 25, 428-438.	1.0	13
194	Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics, 2012, 13, 1937-1950.	1.3	26
195	The Troubling Persistence of Race in Pharmacogenomics. Journal of Law, Medicine and Ethics, 2012, 40, 873-885.	0.9	11
196	Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. International Journal of Clinical Pharmacy, 2012, 34, 837-844.	2.1	20
197	Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clinical Biochemistry, 2012, 45, 397-401.	1.9	17
198	Copy number variation and warfarin dosing: evaluation of <i>CYP2C9</i>,<i>VKORC1</i>,<i>CYP4F2</i>,<i>GGCX</i>and<i>CALU</i>. Pharmacogenomics, 2012, 13, 297-307.	1.3	13
199	Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics, 2012, 13, 1239-1245.	1.3	11
200	Therapeutic Dosing of Acenocoumarol: Proposal of a Population Specific Pharmacogenetic Dosing Algorithm and Its Validation in North Indians. PLoS ONE, 2012, 7, e37844.	2.5	39
201	Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics, 2012, 13, 1141-1147.	1.3	32
202	Personalized approach of medication by indirect anticoagulants tailored to the patientâ€"Russian context: what are the prospects?. EPMA Journal, 2012, 3, 10.	6.1	4
203	A Pharmacokineticâ€"Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy. Clinical Pharmacokinetics, 2012, 51, 41-53.	3.5	26
204	NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice. Pharmacogenomics, 2012, 13, 1307-1313.	1.3	4
205	Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thrombosis and Haemostasis, 2012, 108, 781-788.	3.4	20
207	Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. Thrombosis Research, 2012, 130, 435-440.	1.7	26

#	ARTICLE	IF	CITATIONS
209	Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics, 2012, 13, 21-29.	1.3	25
210	Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health and Risk Management, 2012, 8, 363.	2.3	17
211	Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. International Journal of Hematology, 2012, 96, 719-728.	1.6	21
213	Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e44064.	2.5	142
214	The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thrombosis and Haemostasis, 2012, 107, 59-68.	3.4	14
215	Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation. Frontiers in Pharmacology, 2012, 3, 183.	3.5	9
216	A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and Haemostasis, 2012, 107, 1083-1091.	3.4	47
217	The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population. Medical Journal of Indonesia, 0, , 108.	0.5	1
218	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thrombosis and Haemostasis, 2012, 107, 232-240.	3.4	62
219	Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the &#8220;Know-Do&#8221; Gap Across the Personalized Medicine Innovation Ecosystem. Current Pharmacogenomics and Personalized Medicine, 2012, 10, 277-287.	0.2	5
220	Predicting warfarin dosage in Europeanâ€"Americans and Africanâ€"Americans using DNA samples linked to an electronic health record. Pharmacogenomics, 2012, 13, 407-418.	1.3	90
221	Oral Anticoagulant Therapy. Chest, 2012, 141, e44S-e88S.	0.8	1,323
222	A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. European Heart Journal, 2012, 33, 165-175.	2.2	68
223	Clinical decision support systems: Potential with pitfalls. Journal of Surgical Oncology, 2012, 105, 502-510.	1.7	33
224	Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenetics and Genomics, 2012, 22, 176-182.	1.5	34
225	Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients. American Journal of Hematology, 2012, 87, 541-544.	4.1	8
226	Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics, 2012, 13, 465-475.	1.3	29
227	Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease. Personalized Medicine, 2012, 9, 395-404.	1.5	3

#	ARTICLE	IF	CITATIONS
228	Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 125-132.	1.6	4
229	Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Journal of Thrombosis and Thrombolysis, 2012, 34, 120-125.	2.1	52
230	Pharmacogenetics and anaesthesia: the value of genetic profiling. Anaesthesia, 2012, 67, 165-179.	3.8	127
231	Genetic, Clinical and Behavioural Determinants of Vitamin K€Antagonist Dose €" Explored Through Multivariable Modelling and Visualization. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 193-198.	2.5	10
232	Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 594-598.	1.5	10
233	An evaluation of gene€"gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. Journal of Thrombosis and Haemostasis, 2012, 10, 767-772.	3.8	15
234	Multivariate analysis of the relation between diet and warfarin dose. European Journal of Clinical Pharmacology, 2012, 68, 321-328.	1.9	22
235	Clinical applications of pharmacogenomics guided warfarin dosing. International Journal of Clinical Pharmacy, 2013, 35, 359-368.	2.1	6
236	Warfarin dose prediction in children using pharmacometric bridging€"comparison with published pharmacogenetic dosing algorithms. European Journal of Clinical Pharmacology, 2013, 69, 1275-1283.	1.9	36
237	CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. European Journal of Clinical Pharmacology, 2013, 69, 789-797.	1.9	29
238	Identification and weighting of the most critical "real-life"drug€"drug interactions with acenocoumarol in a tertiary care hospital. European Journal of Clinical Pharmacology, 2013, 69, 617-627.	1.9	13
239	Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service. Pharmacotherapy, 2013, 33, 1156-1164.	2.6	70
240	Molecular Approaches, Models, and Techniques in Pharmacogenomic Research and Development. , 2013, , 273-294.		1
241	Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly. Drugs and Aging, 2013, 30, 687-699.	2.7	17
242	Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics, 2013, 14, S11.	2.8	14
243	Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. European Journal of Clinical Pharmacology, 2013, 69, 1769-1775.	1.9	15
244	Pharmacogenomics and Cardiovascular Disease. Current Cardiology Reports, 2013, 15, 376.	2.9	12
245	Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis. International Journal of Cardiology, 2013, 168, 4234-4243.	1.7	88

#	ARTICLE	IF	CITATIONS
246	C3435T polymorphism of MDR1 gene with warfarin resistance. Clinica Chimica Acta, 2013, 425, 34-36.	1.1	14
247	Comparison of initial warfarin response in obese patients versus non-obese patients. Journal of Thrombosis and Thrombolysis, 2013, 36, 96-101.	2.1	68
248	The future of inpatient anticoagulation management. Journal of Thrombosis and Thrombolysis, 2013, 35, 375-386.	2.1	0
249	Genetics of Population Differences in Drug Response. Current Genetic Medicine Reports, 2013, 1, 162-170.	1.9	40
250	Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors. Clinical Pharmacokinetics, 2013, 52, 567-581.	3.5	16
251	Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. Pharmacological Reports, 2013, 65, 1375-1382.	3.3	24
252	Warfarin pharmacogenetics: A controlled dose–response study in healthy subjects. Vascular Medicine, 2013, 18, 290-297.	1.5	7
253	Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics, 2013, 14, 1593-1603.	1.3	47
254	Pharmacogenomics: Historical Perspective and Current Status. Methods in Molecular Biology, 2013, 1015, 3-22.	0.9	17
255	A Systems Approach to Designing Effective Clinical Trials Using Simulations. Circulation, 2013, 127, 517-526.	1.6	19
257	Pharmacogenetics and Cardiovascular Disease–Implications for Personalized Medicine. Pharmacological Reviews, 2013, 65, 987-1009.	16.0	109
258	A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. New England Journal of Medicine, 2013, 369, 2283-2293.	27.0	660
260	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. American Heart Journal, 2013, 166, 435-441.e2.	2.7	15
261	Clinical Decision Support. , 2013, , 324-331.		2
262	Validation of a Proposed Warfarin Dosing Algorithm Based on the Genetic Make-Up of Egyptian Patients. Molecular Diagnosis and Therapy, 2013, 17, 381-390.	3.8	20
263	Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update. Circulation, 2013, 128, 2813-2851.	1.6	100
264	A Bayesian Dose-Individualization Method for Warfarin. Clinical Pharmacokinetics, 2013, 52, 59-68.	3.5	41
265	The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thrombosis Research, 2013, 131, 125-129.	1.7	20

#	Article	IF	Citations
266	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thrombosis and Haemostasis, 2013, 109, 146-153.	3.4	30
267	Anticoagulant Drugs: Current and Novel. , 2013, , 113-141.		2
268	Pharmacogenomics discovery and implementation in genomeâ€wide association studies era. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 1-9.	6.6	25
269	Pharmacogenomics and Heart Failure in Congenital Heart Disease. Canadian Journal of Cardiology, 2013, 29, 779-785.	1.7	1
270	Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use. Value in Health, 2013, 16, S16-S19.	0.3	7
271	Pharmacogenomics of warfarin in populations of <scp>A</scp>frican descent. British Journal of Clinical Pharmacology, 2013, 75, 334-346.	2.4	34
273	Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thrombosis Research, 2013, 131, 363-367.	1.7	14
274	Pharmacogenetics and Pharmacogenomics. , 2013, , 362-371.		0
275			

#	ARTICLE	IF	CITATIONS
285	Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. Archives of Pathology and Laboratory Medicine, 2013, 137, 1232-1236.	2.5	27
286	Stroke Pharmacogenetics. , 2013, , 223-297.		0
287	Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. Pathology, 2013, 45, 357-370.	0.6	4
289	Clopidogrel and warfarin pharmacogenetic tests. Current Opinion in Cardiology, 2013, 28, 305-314.	1.8	15
290	Warfarin pharmacogenetics: How close are we to clinical practice?. Indian Journal of Human Genetics, 2013, 19, 277.	0.7	1
291	Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice. ISRN Pharmacology, 2013, 2013, 1-17.	1.6	50
292	The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging. , 2013, , 367-404.		1
293	Machine learning based prediction of warfarin optimal dosing for African American patients. , 2013, , .		7
294	Impact of Genetic Factors (<i><scp>CYP2C9</scp></i>,<i><scp>VKORC1</scp></i> and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 427 Td (Clinical Pharmacology and Toxicology, 2013, 112, 209-214.	2.5	28
295	Evaluation of warfarin resistance using transcription activator–like effector nucleases–mediated vitamin K epoxide reductase knockout HEK293 cells. Journal of Thrombosis and Haemostasis, 2013, 11, 1556-1564.	3.8	55
296	Pharmacogenetics of Oral Anticoagulants. , 2013, , 435-467.		0
297	Warfarin pharmacogenomics in children. Pediatric Blood and Cancer, 2013, 60, 1402-1407.	1.5	16
299	Vertical Integration of Pharmacogenetics in Population PK/PD Modeling: A Novel Information Theoretic Method. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-10.	2.5	8
300	Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant Therapy. International Journal of Genomic Medicine, 2013, 1, .	0.0	1
301	Pharmacogenetics in Cardiovascular Diseases. , 2013, , 133-182.		3
302	The Need for Clinical Decision Support Integrated with the Electronic Health Record for the Clinical Application of Whole Genome Sequencing Information. Journal of Personalized Medicine, 2013, 3, 306-325.	2.5	23
303	Translating Pharmacogenomic Research to Therapeutic Potentials. , 2013, , 45-61.		1
304	Comparative genetics of warfarin resistance. Hamostaseologie, 2014, 34, 143-159.	1.9	22

#	ARTICLE	IF	CITATIONS
305	A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. Thrombosis and Haemostasis, 2014, 111, 705-712.	3.4	2
306	A Proposed Clinical Decision Support Architecture Capable of Supporting Whole Genome Sequence Information. Journal of Personalized Medicine, 2014, 4, 176-199.	2.5	14
307	Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum. Korean Journal of Internal Medicine, 2014, 29, 498.	1.7	16
308	Warfarin Pharmacogenomics: Recommendations With Available Patented Clinical Technologies. Recent Patents on Biotechnology, 2014, 8, 110-115.	0.8	6
309	Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area. Current Psychiatry Reviews, 2014, 10, 118-132.	0.9	13
310	A multiplexer liquidchip technology for detecting single nucleotide polymorphisms from metabolism of anti-thrombotic drugs in dried blood spots on filter paper. Acta Biochimica Et Biophysica Sinica, 2014, 46, 522-525.	2.0	3
311	Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. Pharmacogenomics, 2014, 15, 29-37.	1.3	42
312	Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups. Molecular Biology Reports, 2014, 41, 7305-7312.	2.3	12
313	Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service. BioMed Research International, 2014, 2014, 1-5.	1.9	6
314	Pharmacogenomics in Brazil. , 2014, , 1015-1035.		0
315	A New Algorithm for Weekly Phenprocoumon Dose Variation in a Southern Brazilian Population: Role for <scp>CYP</scp>2C9, <scp>CYP</scp>3A4/5 and <scp>VKORC</scp>1 Genes Polymorphisms. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 323-329.	2.5	8
316	Validation of patient-reported warfarin dose in a prospective incident cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 285-289.	1.9	4
317	Warfarin dose requirements in a patient with the <i>CYP2C9*14</i> allele. Pharmacogenomics, 2014, 15, 909-914.	1.3	6
318	The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clinical Genetics, 2014, 86, 21-28.	2.0	68
320	Understanding and preventing drug–drug and drug–gene interactions. Expert Review of Clinical Pharmacology, 2014, 7, 533-544.	3.1	110
321	Pharmacogenetics-based warfarin dosing in children. Pharmacogenomics, 2014, 15, 361-374.	1.3	13
322	Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics, 2014, 15, 2025-2048.	1.3	21
323	Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues. JAMA Internal Medicine, 2014, 174, 1330.	5.1	109

#	Article	IF	Citations
324	Pharmacogenetics in Jewish populations. Drug Metabolism and Drug Interactions, 2014, 29, 221-233.	0.3	14
325	Warfarin Dosing in a Patient with<i>CYP2C9*3*3</i>and<i>VKORC1-1639 AA</i>Genotypes. Case Reports in Genetics, 2014, 2014, 1-4.	0.2	7
326	Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and Genomics, 2014, 24, 501-513.	1.5	10
327	Pharmacogenetic‐guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British Journal of Clinical Pharmacology, 2014, 77, 626-641.	2.4	113
328	Dosage Individualization of Warfarin Using Artificial Neural Networks. Molecular Diagnosis and Therapy, 2014, 18, 371-379.	3.8	25
329	Genetic Risk Factors for Major Bleeding in Patients Treated With Warfarin in a Community Setting. Clinical Pharmacology and Therapeutics, 2014, 95, 636-643.	4.7	34
330	Conserved Loop Cysteines of Vitamin K Epoxide Reductase Complex Subunit 1-like 1 (VKORC1L1) Are Involved in Its Active Site Regeneration. Journal of Biological Chemistry, 2014, 289, 9396-9407.	3.4	29
331	Serious Bleeding Events due to Warfarin and Antibiotic Co-prescription in a Cohort of Veterans. American Journal of Medicine, 2014, 127, 657-663.e2.	1.5	55
332	Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method. European Journal of Clinical Pharmacology, 2014, 70, 265-273.	1.9	12
333	Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics Journal, 2014, 14, 223-228.	2.0	59
334	Applied Pharmacogenomics in Cardiovascular Medicine. Annual Review of Medicine, 2014, 65, 81-94.	12.2	21
335	Warfarin Dosing and Body Mass Index. Annals of Pharmacotherapy, 2014, 48, 584-588.	1.9	35
336	Demographic history and human genetic diversity: pharmacogenomic implications. Pharmacogenomics, 2014, 15, 253-256.	1.3	2
337	Pharmacogenomic implications of population admixture: Brazil as a model case. Pharmacogenomics, 2014, 15, 209-219.	1.3	35
338	Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2014, 12, 1480-1487.	3.8	39
339	Influence of proton pump inhibitors and <i><scp>VKORC</scp>1</i> mutations on <scp>CYP</scp>2C9‐mediated dose requirements of vitamin K antagonist therapy: a pilot study. British Journal of Haematology, 2014, 167, 547-553.	2.5	3
340	Update on Genetic Testing and Warfarin. Current Emergency and Hospital Medicine Reports, 2014, 2, 133-137.	1.5	1
341	Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?. Pharmacogenomics, 2014, 15, 719-722.	1.3	23

#	ARTICLE	IF	CITATIONS
342	Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 319-321.	1.5	2
343	Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 â€" Implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences, 2014, 343, 30-35.	0.6	5
345	Clinical application of pharmacogenomics through clinical exercises and online resources. Currents in Pharmacy Teaching and Learning, 2014, 6, 571-576.	1.0	5
346	The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery. Journal of Thrombosis and Thrombolysis, 2014, 37, 177-185.	2.1	22
347	Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and Haemostasis, 2014, 112, 522-536.	3.4	20
348	Warfarin pharmacogenetics: it matters if youâ€™re black or white. Blood, 2014, 124, 2171-2171.	1.4	6
349	Exosome complex and erythropoiesis. Blood, 2014, 124, 2169-2171.	1.4	2
350	Personalized medicine: importance of clinical interpretative skills for real-world patient care. Personalized Medicine, 2014, 11, 395-408.	1.5	0
351	Race influences warfarin dose changes associated with genetic factors. Blood, 2015, 126, 539-545.	1.4	90
352	Rodenticides. , 2015, , 917-926.		0
353	Pharmacogenomic Testing and Warfarin Management. Oncology Nursing Forum, 2015, 42, 563-565.	1.2	3
354	Determination of Genotypes Using a Fully Automated Molecular Detection System. Archives of Pathology and Laboratory Medicine, 2015, 139, 805-811.	2.5	3
355	Genes affecting warfarin responseâ€"interactive or additive?. Journal of Clinical Pharmacology, 2015, 55, 258-260.	2.0	3
356	Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry. Pharmacogenetics and Genomics, 2015, 25, 491-500.	1.5	4
357	Methods for Predicting Warfarin Dose Requirements. Therapeutic Drug Monitoring, 2015, 37, 531-538.	2.0	16
358	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Therapeutic Drug Monitoring, 2015, 37, 428-436.	2.0	64
359	Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome. Blood Coagulation and Fibrinolysis, 2015, 26, 499-504.	1.0	9
360	PredicciÃ³n de sensibilidad a la warfarina basada en VKORC1 y CYP2C9 en pacientes de diferentes lugares de Colombia. Biomedica, 2015, 36, 91-100.	0.7	2

#	ARTICLE	IF	CITATIONS
361	Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0144511.	2.5	41
362	Revisiting Warfarin Dosing Using Machine Learning Techniques. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-9.	1.3	49
363	The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing. American Journal of Cardiovascular Drugs, 2015, 15, 267-274.	2.2	1
364	Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiology and Drug Safety, 2015, 24, 228-236.	1.9	6
365	Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. Cardiovascular Drugs and Therapy, 2015, 29, 257-264.	2.6	3
366	Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thrombosis Research, 2015, 135, 861-866.	1.7	15
367	Oral anticoagulation: a critique of recent advances and controversies. Trends in Pharmacological Sciences, 2015, 36, 153-163.	8.7	70
368	Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of Medical Research, 2015, 46, 265-273.	3.3	18
369	STATISTICAL METHODS FOR PERSONALIZED MEDICINE. , 2015, , 79-102.		1
370	Use of genetic data to guide therapy in arterial disease. Journal of Thrombosis and Haemostasis, 2015, 13, S281-S289.	3.8	10
371	Pharmacogenetics of coumarin anticoagulants in Brazilians. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 67-79.	3.3	13
372	The Use of Warfarin for DVT Prophylaxis Following Hip and Knee Arthroplasty: How Often Are Patients Within Their Target INR Range?. Journal of Arthroplasty, 2015, 30, 315-319.	3.1	22
373	Genotype-Guided Dosing of Coumarin Anticoagulants. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 387-394.	2.0	20
374	A Bayesian Estimation Framework for Pharmacogenomics Driven Warfarin Dosing: A Comparative Study. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1724-1733.	6.3	12
375	Genotype-guided coumarin dosing: where are we now and where do we need to go next?. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 509-522.	3.3	4
376	Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics Journal, 2015, 15, 443-451.	2.0	91
377	Factors influencing pharmacokinetics of warfarin in African–Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics, 2015, 16, 217-225.	1.3	14
378	Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs. Personalized Medicine Universe, 2015, 4, 13-22.	0.3	0

#	ARTICLE	IF	CITATIONS
379	Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascular Pharmacology, 2015, 74, 151-157.	2.1	5
380	Paediatric models in motion: requirements for model-based decision support at the bedside. British Journal of Clinical Pharmacology, 2015, 79, 85-96.	2.4	21
381	Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization. Personalized Medicine, 2015, 12, 117-128.	1.5	3
382	Future Translational Applications From the Contemporary Genomics Era. Circulation, 2015, 131, 1715-1736.	1.6	38
383	Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thrombosis Research, 2015, 135, 621-629.	1.7	28
384	Mobile Compression Devices and Aspirin for VTE Prophylaxis Following Simultaneous Bilateral Total Knee Arthroplasty. Journal of Arthroplasty, 2015, 30, 447-450.	3.1	17
385	Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics, 2015, 16, 583-590.	1.3	49
386	Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest, 2015, 148, 701-710.	0.8	26
387	CYP450 pharmacogenomics: a cardiology perspective. Personalized Medicine, 2015, 12, 59-62.	1.5	0
388	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	6.1	86
389	Genomic Medicine Today. , 2015, , 9-25.		0
390	Mechanistic insights into the effect of *CYP2C9*2* and *CYP2C9*3* variants on the 7-hydroxylation of warfarin. Pharmacogenomics, 2015, 16, 393-400.	1.3	3
391	Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenetics and Genomics, 2015, 25, 73-81.	1.5	79
392	Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements. Biochemical Genetics, 2015, 53, 334-350.	1.7	1
393	International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. Pharmacogenomics, 2015, 16, 1109-1118.	1.3	14
394	Body mass index predicts major bleeding risks in patients on warfarin. Journal of Thrombosis and Thrombolysis, 2015, 40, 494-498.	2.1	30
395	Pharmacogenetics of Coumarin Anticoagulant Therapy. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 307-328.	0.6	2
396	Comparison of the Performance of the Warfarin Pharmacogenetics Algorithms in Patients with Surgery of Heart Valve Replacement and Heart Valvuloplasty. Thrombosis Research, 2015, 136, 552-559.	1.7	7

#	ARTICLE	IF	CITATIONS
398	Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics, 2015, 16, 1253-1263.	1.3	29
399	Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients. Pharmacogenomics, 2015, 16, 1465-1474.	1.3	14
400	Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. Journal of Cardiology, 2015, 65, 178-184.	1.9	11
401	Personalized Genomes and Cardiovascular Disease. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a014068-a014068.	6.2	7
402	Effect of CYP2C9â€"VKORC1 interaction on warfarin stable dosage and its predictive algorithm. Journal of Clinical Pharmacology, 2015, 55, 251-257.	2.0	19
403	Warfarin pharmacogenetics. Trends in Cardiovascular Medicine, 2015, 25, 33-41.	4.9	128
404	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annual Review of Pharmacology and Toxicology, 2015, 55, 89-106.	9.4	442
405	Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. Journal of Thrombosis and Thrombolysis, 2015, 39, 228-234.	2.1	20
406	Is personalized medicine a dream or a reality?. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 1-11.	6.1	24
408	An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Thrombosis and Haemostasis, 2016, 116, 337-348.	3.4	15
409	Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei Medical Journal, 2016, 57, 635.	2.2	13
410	INR Stability, Clinical Importance, and Predictors in Patients With Atrial Fibrillation and Venous Thromboembolism Receiving Vitamin K Antagonists. Journal of Pharmacy Technology, 2016, 32, 253-259.	1.0	1
411	A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS ONE, 2016, 11, e0150456.	2.5	17
412	Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. Journal of Cardiovascular Pharmacology, 2016, 67, 86-92.	1.9	28
413	Pharmacogenomics. Journal of Infusion Nursing, 2016, 39, 139-148.	2.3	1
414	Evaluation of 16 genotype-guided Warfarin Dosing Algorithms in 310 Korean Patients Receiving Warfarin Treatment: Poor Prediction Performance in VKORC1 1173C Carriers. Clinical Therapeutics, 2016, 38, 2666-2674.e1.	2.5	13
415	Genetic Polymorphisms and <i>in Vitro</i> Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants. Biological and Pharmaceutical Bulletin, 2016, 39, 1748-1759.	1.4	32
416	The future of epidemiology: methods or matter?. International Journal of Epidemiology, 2016, 45, 1699-1716.	1.9	8

#	Article	IF	Citations
417	Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range â€" study protocol for a randomized controlled trial. BMC Cardiovascular Disorders, 2016, 16, 224.	1.7	6
418	A modifiable microarray-based universal sensor: providing sample-to-results automation. Heliyon, 2016, 2, e00179.	3.2	3
419	Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke, 2016, 47, 1555-1561.	2.0	53
420	Predicting prolonged dose titration in patients starting warfarin. Pharmacoepidemiology and Drug Safety, 2016, 25, 1228-1235.	1.9	5
421	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics, 2016, 17, 1425-1439.	1.3	21
422	Fundamentals of Pharmacogenetics in Personalized, Precision Medicine. Clinics in Laboratory Medicine, 2016, 36, 447-459.	1.4	15
423	Impact of *GGCX, STX1B* and *FPGS* Polymorphisms on Warfarin Dose Requirements in Europeanâ€Americans and Egyptians. Clinical and Translational Science, 2016, 9, 36-42.	3.1	8
424	Development of neuro-fuzzy model to explore geneâ€"nutrient interactions modulating warfarin dose requirement. Pharmacogenomics, 2016, 17, 1315-1325.	1.3	3
425	Clinical and regulatory considerations in pharmacogenetic testing. American Journal of Health-System Pharmacy, 2016, 73, 1999-2006.	1.0	6
426	The Personalization of Drug Therapy for Elderly Patients. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 589-611.	0.6	0
427	Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. Pharmacogenomics, 2016, 17, 1891-1901.	1.3	14
428	Age and the Process of Aging. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 67-86.	0.6	2
429	Use of signals and systems engineering to improve the safety of warfarin initiation. Journal of Thrombosis and Thrombolysis, 2016, 42, 529-533.	2.1	0
430	Coumarin anticoagulants. , 2016, , 702-737.		0
431	A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenetics and Genomics, 2016, 26, 445-452.	1.5	5
432	Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool. Therapeutic Drug Monitoring, 2016, 38, 677-683.	2.0	10
433	Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin. American Journal of Cardiology, 2016, 118, 232-236.	1.6	6
434	Warfarin Pharmacogenetics Reevaluated. American Journal of Clinical Pathology, 2016, 145, 671-686.	0.7	3

#	ARTICLE	IF	CITATIONS
435	Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese population. Lipids in Health and Disease, 2016, 15, 34.	3.0	7
436	Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?. Journal of the American Heart Association, 2016, 5, e003440.	3.7	3
437	eHealth: past and future perspectives. Personalized Medicine, 2016, 13, 57-70.	1.5	34
438	Cardiovascular Pharmacogenomicsâ€"Implications for Patients With CKD. Advances in Chronic Kidney Disease, 2016, 23, 82-90.	1.4	12
439	Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical Reports, 2016, 4, 498-506.	2.0	26
440	Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. Pharmacogenomics, 2016, 17, 121-131.	1.3	17
441	Pharmacogenetics and oral antithrombotic drugs. Current Opinion in Pharmacology, 2016, 27, 38-42.	3.5	24
442	Warfarin Dosing Algorithms and the Need for Human Intervention. American Journal of Medicine, 2016, 129, 431-437.	1.5	7
443	PGWD: Integrating Personal Genome for Warfarin Dosing. Interdisciplinary Sciences, Computational Life Sciences, 2016, 8, 23-27.	3.6	0
444	Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics Journal, 2017, 17, 47-52.	2.0	16
445	The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20 years. Blood Cells, Molecules, and Diseases, 2017, 67, 54-58.	1.4	1
446	The effect of amiodarone on warfarin anticoagulation: a registerâ€based nationwide cohort study involving the Swedish population. Journal of Thrombosis and Haemostasis, 2017, 15, 446-453.	3.8	20
447	Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. Journal of Thrombosis and Haemostasis, 2017, 15, 735-743.	3.8	3
448	Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring â‰¥7 mg Daily: A Systematic Review and Metaâ€analysis. Clinical Pharmacology and Therapeutics, 2017, 102, 297-304.	4.7	16
449	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogeneticsâ€Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 2017, 102, 397-404.	4.7	479
450	The association between <i>GGCX, miR-133</i> genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 438-445.	1.5	5
451	Genotype-guided dosing of warfarin through modeling and simulation. European Journal of Pharmaceutical Sciences, 2017, 109, S9-S14.	4.0	10
452	Engaging Hmong adults in genomicÂandÂpharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach. Journal of Community Genetics, 2017, 8, 117-125.	1.2	23

#	ARTICLE	IF	CITATIONS
453	Pharmacogenetics and Pharmacogenomics. , 2017, , 233-246.		2
454	Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Molecular Diagnosis and Therapy, 2017, 21, 75-83.	3.8	7
455	Matching phenotypes to whole genomes: Lessons learned from four iterations of the personal genome project community challenges. Human Mutation, 2017, 38, 1266-1276.	2.5	14
456	Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting. Physiological Genomics, 2017, 49, 346-354.	2.3	8
457	Pharmacogenetics and Pharmacogenomics. , 2017, , 89-107.		3
458	Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. Pharmacogenomics, 2017, 18, 891-910.	1.3	15
459	STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. , 2017, 22, 545-556.		6
460	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2017, 318, 1115.	7.4	198
461	Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy, 2017, 37, 1366-1373.	2.6	5
462	Study on a novel polymorphism in the VKORC1 promoter region using bioinformatic tools and warfarin dosing data. Thrombosis Research, 2017, 158, 76-78.	1.7	6
463	Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Pharmacogenetics and Genomics, 2017, 27, 347-355.	1.5	21
464	Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy, 2017, 37, 1150-1163.	2.6	77
465	Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement. Pharmacogenomics, 2017, 18, 1051-1057.	1.3	6
466	Anticoagulation Endpoints With Clinical Implementation of Warfarin Pharmacogenetic Dosing in a Realâ€World Setting: A Proposal for a New Pharmacogenetic Dosing Approach. Clinical Pharmacology and Therapeutics, 2017, 101, 675-683.	4.7	24
468	Cardiovascular pharmacogenetics: a promise for genomicallyâ€guided therapy and personalized medicine. Clinical Genetics, 2017, 91, 355-370.	2.0	31
469	3. Pharmakogenetik In Der Praxis. , 2017, , 218-440.		0
470	Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. Frontiers in Pharmacology, 2017, 8, 323.	3.5	21
471	Personalized Medicine in Cardiovascular Disease. , 2017, , 457-471.		1

#	ARTICLE	IF	CITATIONS
472	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine, 2017, 7, 20.	2.5	12
473	Precision Medicine in Primary Health Care. , 2017, , 101-113.		0
474	Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Annals of Laboratory Medicine, 2017, 37, 180-193.	2.5	15
475	Molecular Diagnostics for Coagulopathies. , 2017, , 221-233.		0
476	Pharmacogenetics-based warfarin dose prediction algorithm for patients with heart valve replacement in Southeast China. Genetics and Molecular Research, 2017, 16, .	0.2	1
477	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. , 2018, , 119-172.		0
478	Comparative performance of pharmacogeneticsâ€based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population. Cardiovascular Therapeutics, 2018, 36, e12315.	2.5	7
479	Emerging Role of Precision Medicine in Cardiovascular Disease. Circulation Research, 2018, 122, 1302-1315.	4.5	218
480	Genotype-guided warfarin therapy: current status. Pharmacogenomics, 2018, 19, 667-685.	1.3	38
481	Current strategies to streamline pharmacotherapy for older adults. European Journal of Pharmaceutical Sciences, 2018, 111, 432-442.	4.0	12
482	VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. Future Cardiology, 2018, 14, 15-26.	1.2	4
483	The Role of Clinical Variables and VKORC1 Polymorphism in Efficacy and Stability of Acenocoumarol in Neurological Patients. Journal of Neurosciences in Rural Practice, 2018, 09, 186-192.	0.8	1
484	Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 169-178.	0.7	12
485	Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics, 2018, 19, 1357-1371.	1.3	28
487	Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. Oncotarget, 2018, 9, 29238-29258.	1.8	26
488	Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS). Drug Metabolism and Pharmacokinetics, 2018, 33, 258-263.	2.2	9
489	Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery. Thrombosis Research, 2018, 171, 167-170.	1.7	4
490	Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose. PLoS ONE, 2018, 13, e0205872.	2.5	73

#	ARTICLE	IF	CITATIONS
491	Pharmacogenetics in Cardiovascular Medicine. Advances in Pharmacology, 2018, 83, 333-360.	2.0	5
492	Clinical Pharmacogenomics. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1561-1571.	4.5	18
493	Cytochrome P450 in Pharmacogenetics: An Update. Advances in Pharmacology, 2018, 83, 3-32.	2.0	113
494	A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-11.	1.3	8
495	Warfarin maintenance dose Prediction for Patients undergoing heart valve replacementâ€" a hybrid model with genetic algorithm and Back-Propagation neural network. Scientific Reports, 2018, 8, 9712.	3.3	16
496	A simple, sensitive, and high-throughput LC-APCI-MS/MS method for simultaneous determination of vitamin K1, vitamin K1 2,3-epoxide in human plasma and its application to a clinical pharmacodynamic study of warfarin. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 82-91.	2.8	14
497	Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population. European Journal of Clinical Pharmacology, 2018, 74, 1555-1566.	1.9	6
498	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine, 2018, 8, 1.	2.5	136
499	Pharmacogenetic Warfarin Dosing Algorithms: Validity in Egyptian Patients. Acta Haematologica, 2018, 139, 255-262.	1.4	5
500	Additive manufacturing of pharmaceuticals for precision medicine applications: A review of the promises and perils in implementation. Additive Manufacturing, 2018, 23, 319-328.	3.0	36
501	Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. Blood, 2018, 132, 1974-1984.	1.4	24
502	Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases. , 2018, , 731-743.		3
503	Majority of Total Joint Arthroplasties Are Subtherapeutic on Warfarin at Time of Discharge: Another Reason to Avoid Warfarin as a Venous Thromboembolism Prophylaxis?. Journal of Arthroplasty, 2018, 33, 2787-2791.	3.1	2
504	Omics Approaches Towards Transforming Personalized Medicine. , 2018, , 25-46.		0
505	Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 207-216.	2.1	15
506	Population Diversity in Pharmacogenetics: A Latin American Perspective. Advances in Pharmacology, 2018, 83, 133-154.	2.0	24
507	Pharmacogenetics of therapeutics. , 2019, , 41-74.		0
508	An Expert System to Predict Warfarin Dosage in Turkish Patients Depending on Genetic and Non-Genetic Factors. , 2019, , .		7

#	Article	IF	Citations
510	Providers' utilization and perceptions of warfarin dosing algorithms. Thrombosis Research, 2019, 183, 4-12.	1.7	3
511	Oral Anticoagulant Therapyâ€"When Art Meets Science. Journal of Clinical Medicine, 2019, 8, 1747.	2.4	13
512	Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery. European Journal of Clinical Pharmacology, 2019, 75, 1685-1693.	1.9	12
513	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2019, 322, 834.	7.4	9
514	Translating Pharmacogenomic Research to Therapeutic Potentials. , 2019, , 103-122.		0
515	Pharmacogenetics in Cardiovascular Diseases. , 2019, , 133-179.		3
516	The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging and Pharmacovigilance. , 2019, , 289-327.		1
517	Pharmacogenomics in Latin American Populations. , 2019, , 329-368.		1
518	Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients â€" a randomized, prospective study. Pharmacogenomics Journal, 2019, 19, 446-454.	2.0	7
519	Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 449-458.	3.3	7
520	Warfarin in nonvalvular atrial fibrillationâ€"Time for a change?. Seminars in Dialysis, 2019, 32, 520-526.	1.3	5
521	The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. European Journal of Clinical Pharmacology, 2019, 75, 1387-1392.	1.9	7
522	Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy. Journal of Thrombosis and Thrombolysis, 2019, 48, 570-579.	2.1	3
523	Pharmacogenetics of Warfarin in a Diverse Patient Population. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 521-533.	2.0	15
524	Genetic polymorphisms and dosing of vitamin K antagonist in Indian patients after heart valve surgery. Indian Journal of Thoracic and Cardiovascular Surgery, 2019, 35, 539-547.	0.6	0
525	The Genetics of Warfarin Doseâ€"Response Variability in Africans: An Expert Perspective on Past, Present, and Future. OMICS A Journal of Integrative Biology, 2019, 23, 152-166.	2.0	10
526	Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients. European Journal of Clinical Pharmacology, 2019, 75, 901-911.	1.9	11
527	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. Clinical Pharmacokinetics, 2019, 58, 1077-1089.	3.5	12

#	Article	IF	Citations
528	Warfarin dose requirement in patients having severe thrombosis or thrombophilia. British Journal of Clinical Pharmacology, 2019, 85, 1684-1691.	2.4	10
529	Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. Genes, 2019, 10, 261.	2.4	13
530	Evaluation of the predictive performance of Bayesian dosing for warfarin in Chinese patients. Pharmacogenomics, 2019, 20, 167-177.	1.3	6
531	Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 1-8.	0.7	9
532	Precision dosing of warfarin: open questions and strategies. Pharmacogenomics Journal, 2019, 19, 219-229.	2.0	17
533	Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario. Indian Journal of Thoracic and Cardiovascular Surgery, 2019, 35, 3-44.	0.6	4
534	Cases in Precision Medicine: The Role of Pharmacogenetics in Precision Prescribing. Annals of Internal Medicine, 2019, 170, 796.	3.9	8
535	A Computer-Aided System for Determining the Application Range of a Warfarin Clinical Dosing Algorithm Using Support Vector Machines with a Polynomial Kernel Function. , 2019, , .		1
536	Pharmacogenomics research and clinical implementation in Brazil. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 538-549.	2.5	17
537	Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients. OMICS A Journal of Integrative Biology, 2019, 23, 36-44.	2.0	11
538	The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin. European Journal of Clinical Pharmacology, 2019, 75, 343-350.	1.9	1
539	Conference report: pharmacogenomics in special populations at WCP2018. British Journal of Clinical Pharmacology, 2019, 85, 467-475.	2.4	3
540	Pharmacogenomics and Precision Medicine. , 2019, , 437-451.		2
541	Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 197-208.	1.5	20
542	Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Buddâ€"Chiari syndrome on warfarin. Hepatology International, 2019, 13, 214-221.	4.2	11
543	*CYP2C9*61*, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics, 2019, 20, 3-8.	1.3	5
544	Population-scale genomicsâ€"Enabling precision public health. Advances in Genetics, 2019, 103, 119-161.	1.8	9
545	Effect of *CYP4F2*, *VKORC1*, and *CYP2C9* in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23

#	ARTICLE	IF	CITATIONS
546	Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?. Annual Review of Pharmacology and Toxicology, 2019, 59, 577-603.	9.4	19
547	Pharmaconutrigenetics: The Impact of Genetics on Nutrientâ€"Drug Interactions. , 2020, , 519-524.		0
548	Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. Pharmacogenomics Journal, 2020, 20, 104-113.	2.0	13
549	Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. European Journal of Clinical Pharmacology, 2020, 76, 199-209.	1.9	7
550	Gene-based anticoagulation regimens for an infant after mitral-valve replacement. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		0
551	Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With <i>VKORC1</i> 1173C. Annals of Laboratory Medicine, 2020, 40, 216-223.	2.5	0
552	Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarinâ€"sorafenib interactions in whites and Asians. Pharmacogenomics, 2020, 21, 853-862.	1.3	1
553	Evaluation of inter-patient variability in the pharmacodynamic indices of warfarin. Expert Review of Cardiovascular Therapy, 2020, 18, 835-840.	1.5	7
554	Effects of rare <i>CYP2C9</i> alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation. Pharmacogenomics, 2020, 21, 1021-1031.	1.3	4
555	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	2.8	39
556	Pharmacogenomics in Precision Medicine. , 2020, , .		1
557	Effect of ABO Blood Groups on the Response to Warfarin. American Journal of the Medical Sciences, 2020, 360, 50-54.	1.1	1
559	CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. Pharmacogenomics Journal, 2020, 20, 687-694.	2.0	8
560	Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study. Scientific Reports, 2020, 10, 6988.	3.3	6
561	Impact of CYP2C9â€"Interacting Drugs on Warfarin Pharmacogenomics. Clinical and Translational Science, 2020, 13, 941-949.	3.1	13
562	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. International Journal of Cardiology, 2020, 317, 159-166.	1.7	2
563	Sublethal dose of warfarin induction promotes the accumulation of warfarin resistance in susceptible Norway rats. Journal of Pest Science, 2021, 94, 805-815.	3.7	3
564	Developing and Validating a Clinical Warfarin Doseâ€"Initiation Model for Blackâ€"African Patients in South Africa and Uganda. Clinical Pharmacology and Therapeutics, 2021, 109, 1564-1574.	4.7	8

#	ARTICLE	IF	CITATIONS
565	Implications of Polymorphisms in the BCKDK and GATAâ€4 Gene Regions on Stable Warfarin Dose in African Americans. Clinical and Translational Science, 2021, 14, 492-496.	3.1	0
566	Warfarin dosing algorithms: A systematic review. British Journal of Clinical Pharmacology, 2021, 87, 1717-1729.	2.4	43
567	Multiâ€site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clinical and Translational Science, 2021, 14, 268-276.	3.1	7
568	Impact of adherence to warfarin therapy during 12Âweeks of pharmaceutical care in patients with poor time in the therapeutic range. Journal of Thrombosis and Thrombolysis, 2021, 51, 1043-1049.	2.1	3
569	Pharmacodynamics and Pharmacokinetics of Stroke Therapy. , 2021, , 41-69.		0
570	A Post-Hoc Interpretable Ensemble Model to Feature Effect Analysis in Warfarin Dose Prediction for Chinese Patients. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 840-851.	6.3	3
571	Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient. Frontiers in Pharmacology, 2021, 12, 619339.	3.5	1
572	Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals. Journal of Personalized Medicine, 2021, 11, 94.	2.5	7
573	In Vivo Functional Effects of <i>CYP2C9 M1L,</i> a Novel and Common Variant in the Yupâ€™ik Alaska Native Population. Drug Metabolism and Disposition, 2021, 49, 345-352.	3.3	5
574	Embracing Genetic Diversity to Improve Black Health. New England Journal of Medicine, 2021, 384, 1163-1167.	27.0	71
575	An ensemble learning based framework to estimate warfarin maintenance dose with cross-over variables exploration on incomplete data set. Computers in Biology and Medicine, 2021, 131, 104242.	7.0	12
576	An Adapted Neural-Fuzzy Inference System Model Using Preprocessed Balance Data to Improve the Predictive Accuracy of Warfarin Maintenance Dosing in Patients After Heart Valve Replacement. Cardiovascular Drugs and Therapy, 2022, 36, 879-889.	2.6	5
577	Comparison of multivariate linear regression and a machine learning algorithm developed for prediction of precision warfarin dosing in a Korean population. Journal of Thrombosis and Haemostasis, 2021, 19, 1676-1686.	3.8	17
578	Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 2021, 18, 649-665.	13.7	49
579	Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Scientific Reports, 2021, 11, 10851.	3.3	20
580	Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial. Journal of Clinical Medicine, 2021, 10, 2949.	2.4	4
581	Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients. PeerJ, 2021, 9, e11549.	2.0	7
582	Status Toward the Implementation of Precision Dosing in Children. Journal of Clinical Pharmacology, 2021, 61, S36-S51.	2.0	8

#	ARTICLE	IF	CITATIONS
583	Pharmacogenetic determinants of warfarin in the Indian population. Pharmacological Reports, 2021, 73, 1396-1404.	3.3	5
584	Pharmacogenomics in Cardiovascular Diseases. Current Protocols, 2021, 1, e189.	2.9	7
585	Evaluating the Effect of Longitudinal Dose and INR Data on Maintenance Warfarin Dose Predictions. , 2021, , .		0
586	THE EFFECTS OF GENETIC AND NON GENETIC FACTORS ON WARFARIN DOSE RESPONSE IN VENOUS THROMBOEMBOLISM. , 2021, , 4-5.		0
587	Predicting Range of Initial Warfarin Dose Based on Pharmacometabolomic and Genetic Inputs. Clinical Pharmacology and Therapeutics, 2021, 110, 1585-1594.	4.7	5
588	Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). PLoS ONE, 2021, 16, e0251665.	2.5	7
589	Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients. Genes, 2021, 12, 1537.	2.4	1
590	Profiling of warfarin pharmacokinetics—associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics—dosing algorithm. Journal of Thrombosis and Haemostasis, 2021, 19, 2957-2973.	3.8	14
591	Oral Anticoagulants and Precision Medicine: Something Old, Something New. Clinical Pharmacology and Therapeutics, 2020, 107, 1273-1277.	4.7	5
592	An Introduction to Pharmacogenomics and Personalized Medicine. , 2015, , 1053-1065.		1
593	Cardiovascular Disease Pharmacogenomics. , 2013, , 417-433.		1
594	Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population. Pharmacogenetics and Genomics, 2017, 27, 210-211.	1.5	6
595	Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Medicine (United States), 2020, 99, e22987.	1.0	4
596	Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy. Blood Advances, 2020, 4, 2202-2212.	5.2	13
597	Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation. PLoS ONE, 2011, 6, e27808.	2.5	62
598	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. PLoS ONE, 2013, 8, e64469.	2.5	16
599	Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin. PLoS ONE, 2013, 8, e74053.	2.5	16
600	Verification of Pharmacogenetics-Based Warfarin Dosing Algorithms in Han-Chinese Patients Undertaking Mechanic Heart Valve Replacement. PLoS ONE, 2014, 9, e94573.	2.5	15

#	ARTICLE	IF	CITATIONS
601	Determinants of the Over-Anticoagulation Response during Warfarin Initiation Therapy in Asian Patients Based on Population Pharmacokinetic-Pharmacodynamic Analyses. PLoS ONE, 2014, 9, e105891.	2.5	17
602	A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction. PLoS ONE, 2014, 9, e114896.	2.5	12
603	Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database. PLoS ONE, 2015, 10, e0135784.	2.5	52
604	A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PLoS ONE, 2015, 10, e0145318.	2.5	27
605	Effect of <i>CYP2C9 *11/*11</i> genotype on initial and long-term warfarin dose requirement and therapeutic response. Pharmacogenomics, 2020, 21, 1271-1277.	1.3	2
606	Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population. Acta Biomedica Scientifica, 2019, 4, 40-44.	0.2	4
607	Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2. Laboratory Medicine Online, 2016, 6, 193.	0.2	4
608	Quality of anticoagulation with warfarin in rural Chhattisgarh, India. Indian Journal of Medical Research, 2020, 152, 303.	1.0	5
609	Practical consideration of genotype imputation: Sample size, window size, reference choice, and untyped rate. Statistics and Its Interface, 2011, 4, 339-351.	0.3	26
610	VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients. Journal of Stroke, 2013, 15, 115.	3.2	10
611	Factores genéticos y ambientales asociados con la respuesta a warfarina en pacientes colombianos. Biomedica, 2010, 30, 410.	0.7	6
612	Pharmacogenomics and Rheumatological Practice. Journal of Clinical Rheumatology and Immunology, 0, , 1-12.	0.4	0
613	Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy. Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49, 271-282.	1.8	2
614	Genetic and Nongenetic Determinants of Variable Warfarin Dose Requirements: A Report from North India. Public Health Genomics, 2022, 25, 52-60.	1.0	4
615	ï¼"ï¼ŽWarfarinã•CYP2C9ï¼ŒVKORC1é°ä¼åš¿. Japanese Journal of Clinical Pharmacology and Therapeutics, 2008, 39, 243-246.	0.0	2
616	Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases. , 2009, , 613-622.		0
617	Chapter 13. Drug Biotransformation. , 2009, , .		0
618	Public Health Concerns Related to Vitamin K Status. , 2009, , 161-193.		0

#	ARTICLE	IF	CITATIONS
619	Public Health Concerns Related to Vitamin K Status. , 2009, , 161-193.		0
620	Warfarin resistance in Japanese population. Nosotchu, 2010, 32, 735-739.	0.1	1
621	FarmacogenÃ©tica de la terapÃ©utica anticoagulante. , 2010, , 113-136.		0
622	The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs. , 2011, , 117-138.		0
624	Influence of Genetic Polymorphisms and Non-Genetic Factors upon Warfarin Maintenance Dose in Japanese Elderly Patients. Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 333-340.	0.1	0
627	Pharmacogenomics, Personalized Medicine and Personalized Justice Influencing the Quality and Practice of Forensic Science. , 2011, , 93-120.		0
632	Current Status of Pharmacogenetics in Antithrombotic Drug Therapy. , 0, , .		0
633	Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon. Swiss Medical Weekly, 2013, 143, w13709.	1.6	1
634	GENETIC FACTORS INFLUENCING THE EFFECTIVENESS AND SAFETY OF LONG-TERM ANTICOAGULANT THERAPY. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 89-94.	1.4	2
636	Personalized Medicine Basic Principles. , 2014, , 1-22.		1
637	Pharmacogenomics and Personalized Medicine: Bridging Genetic Knowledge and Clinical Practice. , 2014, , 1-16.		0
638	Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice. , 2014, , 95-133.		1
639	Pharmacogenetic Testing for Anticoagulant and Antiplatelet Therapies. , 2015, , 173-181.		0
640	Ambulatory Warfarin Management. , 2015, , 27-51.		0
641	Implementation of Genomic Medicine: Tools and Challenges. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 329-347.	0.6	0
642	Personalized Medicine in Vascular Medicine. , 2015, , 1035-1052.		0
644	A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy. Computer Aided Chemical Engineering, 2016, , 2313-2318.	0.5	0
645	Essential Pharmacogenomic Biomarkers in Clinical Practice. , 2016, , 51-74.		0

#	ARTICLE	IF	CITATIONS
646	Concepts in Pharmacogenomics and Personalized Medicine. , 2016, , 1-32.		0
647	Stroke Pharmacogenetics. , 2017, , 327-410.		0
648	Venous Thromboembolism (VTE). , 2017, , .		0
650	Clinical and Laboratory Profile of Patients Presenting With Warfarin Coagulation Abnormality Following Heart Valve Replacement- A Descriptive Study. International Journal of Medical Science and Clinical Invention, 2017, 4, .	0.1	0
651	Genotype-guided warfarin dosing. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-20.	0.0	0
652	Genetic and Demographic Outcomes in a Population of Patients with Headache and Facial Pain. Journal of Behavioral and Brain Science, 2018, 08, 339-350.	0.5	0
653	Influence of Vitamin K Epoxide Reductase Complex 1 Polymorphism on Warfarin Therapy in a Cohort Study of Saudi Patients. International Journal of Pharmacology, 2018, 14, 415-420.	0.3	0
654	Phenomenon of unstable international normalized ratio on warfarin therapy (clinical and) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	0
655	Impact of Cytochrome P450 2C9 Polymorphism on Warfarin Therapy in Saudi Population. International Journal of Pharmacology, 2018, 14, 566-571.	0.3	2
657	Genetic disorders of coagulation. , 2020, , 5532-5546.		0
658	Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds. European Cardiology Review, 2020, 15, e53.	2.2	0
659	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Frontiers in Pharmacology, 2021, 12, 749786.	3.5	10
660	CYP2C9, CYP4F2, VKORC1 Gene Polymorphism in Buryat Population. Russian Journal of Genetics, 2020, 56, 1496-1503.	0.6	4
661	Clinical pharmacogenetics. , 2022, , 189-212.		0
662	Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. , 2020, , .		0
663	Pharmacogenomics of Antithrombotic Drugs. , 2020, , 137-153.		0
664	PGWD: integrating personal genome for warfarin dosing. Interdisciplinary Sciences, Computational Life Sciences, 2015, , .	3.6	0
665	Clinical use of pharmacogenomic tests in 2009. Clinical Biochemist Reviews, 2009, 30, 55-65.	3.3	35

#	ARTICLE	IF	CITATIONS
666	Genetics of warfarin sensitivity in an emergency department population with thromboembolic. Western Journal of Emergency Medicine, 2011, 12, 11-6.	1.1	2
668	CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant. Indian Journal of Medical Research, 2014, 139, 572-8.	1.0	6
669	Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. Puerto Rico Health Sciences Journal, 2014, 33, 97-104.	0.2	6
670	Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII. Hippokratia, 2014, 18, 319-27.	0.3	10
671	Warfarin dosage adjustment strategy in Chinese population. International Journal of Clinical and Experimental Medicine, 2015, 8, 9904-10.	1.3	4
672	Advances in Oral Coagulants. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2013, 23, 150-3.	0.7	0
673	Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review. Iranian Journal of Pharmaceutical Research, 2016, 15, 611-7.	0.5	2
674	Association of Warfarin Therapy with and Genes Polymorphism in Iranian Population. Iranian Journal of Pharmaceutical Research, 2017, 16, 1230-1237.	0.5	3
675	Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9. Hippokratia, 2017, 21, 93-96.	0.3	0
676	Comparison of Two Different Techniques Of Warfarin Dosing Determination - A Chemometrics Study. Iranian Journal of Pharmaceutical Research, 2019, 18, 1010-1019.	0.5	3
677	The importance of including African populations in pharmacogenetics studies of warfarin response. Pharmacogenomics, 2022, 23, 1-4.	1.3	2
678	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?. Journal of Personalized Medicine, 2021, 11, 1180.	2.5	4
679	Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A Systematic and Critical Review of Economic Evaluations. Value in Health, 2022, 25, 461-472.	0.3	1
680	Determining the adjusted initial treatment dose of warfarin anticoagulant medicine using kernel-based support vector regression. Computer Methods and Programs in Biomedicine, 2022, 214, 106589.	4.7	4
681	Electrochemical Sensor for the Direct Determination of Warfarin in Blood. Chemosensors, 2022, 10, 44.	3.6	3
682	Warfarin Dosing in Patients With <i>CYP2C9*5</i> Variant Alleles. Clinical Pharmacology and Therapeutics, 2022, 111, 950-955.	4.7	7
683	Efficacy of Prothrombin Complex Concentrate versus Fresh Frozen Plasma in Patients with Bleeding in the Emergency Department. Haseki Tip Bulteni, 2022, 60, 64-71.	0.3	0
684	Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. International Journal of Clinical Pharmacy, 2022, 44, 599-607.	2.1	8

#	Article	IF	Citations
685	Future of Perioperative Precision Medicine: Integration of Molecular Science, Dynamic Health Care Informatics, and Implementation of Predictive Pathways in Real Time. Anesthesia and Analgesia, 2022, Publish Ahead of Print, .	2.2	4
686	Ethnic Diversity and Warfarin Pharmacogenomics. Frontiers in Pharmacology, 2022, 13, 866058.	3.5	17
687	Precise Warfarin Management through Personalized Modeling and Control with Limited Clinical Data. , 2021, 2021, 5035-5038.		3
688	The Impact of <i>CYP2C9*11</i> Allelic Variant on the Pharmacokinetics of Phenytoin and (<i>S</i>)â€‘Warfarin. Clinical Pharmacology and Therapeutics, 2022, 112, 156-163.	4.7	5
692	Nonlinear Machine Learning in Warfarin Dose Prediction: Insights from Contemporary Modelling Studies. Journal of Personalized Medicine, 2022, 12, 717.	2.5	4
693	Long Short-Term Memory Network for Development and Simulation of Warfarin Dosing Model Based on Time Series Anticoagulant Data. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	0
694	The role of machine learning to predict treatment response and target drug therapies. , 2022, , 131-143.		0
695	Clinical considerations for precision medicine clinical decision support. , 2022, , 175-200.		1
696	Influence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy. Cardiology and Therapy, 0, , .	2.6	0
697	Pharmacokinetic Modeling of Warfarin Ð† â€“ Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals<i>CYP2C9</i> Genotype-Dependent Drug-Drug Interactions of S-Warfarin. Drug Metabolism and Disposition, 2022, 50, 1287-1301.	3.3	8
698	Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement. Medicine (United States), 2022, 101, e29626.	1.0	1
699	Optimizing the dynamic treatment regime of in-hospital warfarin anticoagulation in patients after surgical valve replacement using reinforcement learning. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1722-1732.	4.4	4
700	Pharmacogenomics Informs Cardiovascular Pharmacotherapy. Methods in Molecular Biology, 2022, , 201-240.	0.9	0
701	Warfarin therapy and pharmacogenetics: A narrative review of regional and Iraqi studies. Medical Journal of Babylon, 2022, 19, 324.	0.6	2
702	Chapter 9: Cardiology: Warfarin/<i>CYP2C9</i>, <i>VKORC1</i>, <i>CYP4F2</i> Case. , 2022, , .		0
703	Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists. Journal of Internal Medicine, 2023, 293, 124-127.	6.0	3
704	Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study. Pharmacy Practice, 2022, 20, 01-11.	1.5	0
705	Recent advancements in additive manufacturing techniques employed in the pharmaceutical industry: A bird's eye view. Annals of 3D Printed Medicine, 2022, 8, 100081.	3.1	5

#	ARTICLE	IF	CITATIONS
706	Drugâ€"Drugâ€"Gene Interactions in Cardiovascular Medicine. Pharmacogenomics and Personalized Medicine, 0, Volume 15, 879-911.	0.7	3
707	Implementation of pharmacogenomics: Where are we now?. British Journal of Clinical Pharmacology, 0, , .	2.4	6
709	Optimizing warfarin dosing using deep reinforcement learning. Journal of Biomedical Informatics, 2023, 137, 104267.	4.3	6
711	Concomitant administration of warfarin and toremifene: A case report. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 2383-2386.	1.5	0
712	<scp>Genomewide</scp> Association Study Identifies Copy Number Variants Associated With Warfarin Dose Response and Risk of Venous Thromboembolism in African Americans. Clinical Pharmacology and Therapeutics, 2023, 113, 624-633.	4.7	2
713	Comparison of Maintenance Dose Predictions by Warfarin Dosing Algorithms Based on Chinese and Western Patients. Journal of Clinical Pharmacology, 2023, 63, 569-582.	2.0	1
714	Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs. Current Cardiovascular Risk Reports, 2023, 17, 27-38.	2.0	1
715	Control-Relevant Adaptive Personalized Modeling From Limited Clinical Data for Precise Warfarin Management. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 242-251.	2.3	1
716	An Adaptive Model Predictive Controller to Address the Biovariability in Blood Clotting Response During Therapy With Warfarin. IEEE Transactions on Biomedical Engineering, 2023, , 1-11.	4.2	0
717	Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population. Pharmacological Reports, 2023, 75, 695-704.	3.3	1
718	Warfarin hypersensitivity in the internist's practice: a case report. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3392.	1.4	0
719	The prevalence of pharmacogenetic variants of vitamin K epoxide reductase complex subunit 1 gene (rs9923231), cytochrome P450 family 2 subfamily C member 9 gene (rs1799853) and cytochrome P450 family 3 subfamily-A member-5 gene (rs776746) among 13 ethnic groups of Pakistan. Molecular Biology Reports, 0, , .	2.3	0
720	A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019. Frontiers in Pharmacology, 0, 14, .	3.5	1
721	Deriving mechanismâ€based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 432-443.	2.5	4
722	Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population. Drug Metabolism and Personalized Therapy, 2023, .	0.6	2
723	Cannabis Pharmacogenomics: A Path to Personalized Medicine. Current Issues in Molecular Biology, 2023, 45, 3479-3514.	2.4	2
724	Use of the Electronic Health Record for Monitoring Adverse Drug Reactions. Current Allergy and Asthma Reports, 0, , .	5.3	0
726	A â€œBundle of Careâ€•to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study. JMIR Research Protocols, 0, 12, e46710.	1.0	0

#	ARTICLE	IF	CITATIONS
727	Efficacy of Warfarin Therapy Guided by Pharmacogenetics: A Real-world Investigation Among Han Taiwanese. Clinical Therapeutics, 2023, 45, 662-670.	2.5	2
728	Trends and implementation of preemptive pharmacogenomic testing. , 2024, , 363-381.		0
729	Cardiovascular precision medicine â€" A pharmacogenomic perspective. , 2023, 1, .		0
730	Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations. Pharmacogenomics, 2023, 24, 303-314.	1.3	3
731	Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants. European Journal of Clinical Pharmacology, 2023, 79, 1315-1320.	1.9	0
734	Simulating clinical trials for model-informed precision dosing: using warfarin treatment as a use case. Frontiers in Pharmacology, 0, 14, .	3.5	2
735	Pharmacogenomics in cardiovascular disease. , 2024, , 623-642.		0
736	Kineticâ€"pharmacodynamic model of warfarin for prothrombin timeâ€"international normalized ratio in Japanese patients. British Journal of Clinical Pharmacology, 2024, 90, 828-836.	2.4	0
737	Evaluation of Machine Learning Approaches for Predicting Warfarin Discharge Dose in Cardiac Surgery Patients: Retrospective Algorithm Development and Validation Study. JMIR Cardio, 0, 7, e47262.	1.7	0
738	Machine learning models to predict the warfarin discharge dosage using clinical information of inpatients from South Korea. Scientific Reports, 2023, 13, .	3.3	0
739	Pharmacogenomics in Cardiovascular Diseases. , 2023, , 201-237.		0
740	Pharmacogenetic Algorithms. , 2023, , 105-131.		0
741	Optimizing warfarin dosing for patients with atrial fibrillation using machine learning. Scientific Reports, 2024, 14, .	3.3	0
742	Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?. Pharmacogenomics Journal, 2024, 24, .	2.0	0
743	Nonlinear Mixedâ€Effects Model of Zâ€Endoxifen Concentrations in Tamoxifenâ€Treated Patients from the CEPAM Cohort. Clinical Pharmacology and Therapeutics, 0, , .	4.7	0